Aclidinium bromide vs fluticasone furoate/umeclidinium/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide · Tudorza Pressair

Marketed by Azurity Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT00363896 · Phase 3 · completed

The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).

Reported efficacy

Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)

Result source: NCT03022097

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromidefluticasone furoate/​umeclidinium/​vilanterol
Moderate or severe exacerbations, annualised rate0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT019661070.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Trough FEV1, change0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
SGRQ total, change-3.6 vs -1.9−1.8 vs placebo400/12 μg · wk 52 · n 335NCT01572792
7 other results
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
TDI focal score2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161

Moderate or severe exacerbations, annualised rate

Aclidinium bromide
0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107
fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161

Trough FEV1, change

Aclidinium bromide
0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683

SGRQ total, change

Aclidinium bromide
-3.6 vs -1.9−1.8 vs placebo400/12 μg · wk 52 · n 335NCT01572792
7 other results
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051

TDI focal score

Aclidinium bromide
2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Aclidinium bromide: 5 of 5 rows · fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide
Rows use multiple source trials
fluticasone furoate/​umeclidinium/​vilanterol
Rows use multiple source trials
Time to First Moderate or Severe Exacerbation
time to event · months
NA vs NA placebo months @ 52wk200 μg once-dailya,b,c
NCT00358436 · Phase 3 · monotherapy
NA vs NA FF/VI + UMEC months100/62.5/25a,b,c
NCT02729051 · Phase 3 · registry result, not featured evidence
Dropout rate
14.2%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
25.7%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.1%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
12.6%400µg
NCT00891462 · Phase 3
17.8%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
6.3%400 μg Bid
NCT01001494 · Phase 3
8.7%200 μg Bid
NCT01001494 · Phase 3
44.3%
NCT01966107 · Phase 4
4.4%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
18.3%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
18.3%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
10.5%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
2.9%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
44.7%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
42.6%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
5.8%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
10.5%FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
3.8%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
4.8%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
1.5%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
3.7%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
1.5%400 μg Bid
NCT01001494 · Phase 3
2.9%200 μg Bid
NCT01001494 · Phase 3
—
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.5%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6.5%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
2.6%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
6.8%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
7.1%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
3.5%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
3.9%FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Serious AEs
8%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
10.3%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.9%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.4%400 μg Bid
NCT01120093 · Phase 2
1.4%200 μg Bid
NCT01120093 · Phase 2
0%100 μg Bid
NCT01120093 · Phase 2
3.2%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
4.5%400 μg
NCT01045161 · Phase 3
9.5%400 μg
NCT01045161 · Phase 3
6%200 μg
NCT01045161 · Phase 3
13%200 μg to 400 μg
NCT01045161 · Phase 3
5.6%400 μg Bid
NCT01001494 · Phase 3
4.3%200 μg Bid
NCT01001494 · Phase 3
22.8%
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
0%400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
7.7%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.9%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
5.7%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
5.4%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
4.7%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0%400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
10%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
9.3%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
12.3%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.2%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
14%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.9%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
2.3%
NCT00500318 · Phase 3 · registry result, not featured evidence
0%400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
—FF/UMEC/VIe
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
200 μg Once-dailyd
nasopharyngitis 16.3% (placebo 14.4%)
headache 11.3% (placebo 12.5%)
back pain 4.8% (placebo 4.6%)
NCT00363896 · Phase 3 · monotherapy
show 34 more results
200 μg once-daily
headache 14.2% (placebo 12.7%)
nasopharyngitis 12.7% (placebo 11.3%)
upper respiratory tract infection 10.8% (placebo 9.8%)
NCT00358436 · Phase 3 · monotherapy
400 μg
upper respiratory tract infection 9.4% (placebo 8.9%)
chronic obstructive pulmonary disease 7.9% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400 μg Bid
headache 6.8% (placebo 1.3%)
NCT01120093 · Phase 2
200 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
100 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
400µg
chronic obstructive pulmonary disease 7.4% (placebo 12.4%)
NCT00891462 · Phase 3
200µg
chronic obstructive pulmonary disease 9.2% (placebo 12.4%)
NCT00891462 · Phase 3
400 μg
copd exacerbation 13% (placebo 11.5%)
upper respiratory tract infection 1.7% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
400 μg
copd exacerbation 27.9% (placebo 11.5%)
upper respiratory tract infection 5.4% (placebo 0.5%)
nasopharyngitis 4.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg
copd exacerbation 8.7% (placebo 11.5%)
upper respiratory tract infection 1.6% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg to 400 μg
copd exacerbation 22.7% (placebo 11.5%)
nasopharyngitis 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 0.5%)
NCT01045161 · Phase 3
400 μg Bid
chronic obstructivce pulmonary disease 14.1% (placebo 20.5%)
headache 12.3% (placebo 8.1%)
nasopharyngitis 11.2% (placebo 8.4%)
NCT01001494 · Phase 3
200 μg Bid
chronic obstructivce pulmonary disease 15.9% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 8.4%)
headache 10.8% (placebo 8.1%)
NCT01001494 · Phase 3
urinary tract infection 5% (placebo 4.7%)
upper respiratory tract infection 4.8% (placebo 5.6%)
viral upper respiratory tract infection 4.4% (placebo 3.7%)
NCT01966107 · Phase 4
400 μg
headache 5.2% (placebo 9.7%)
nasopharyngitis 3% (placebo 6.7%)
NCT02375724 · Phase 4 · registry result, not featured evidence
400 μg bid
erythema 10% (placebo 0%)
NCT02153489 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 20.3% (placebo 15.8%)
urinary tract infection 8.2% (placebo 5.5%)
nasopharyngitis 7.7% (placebo 4.8%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 22.1% (placebo 15.8%)
nasopharyngitis 6.9% (placebo 4.8%)
urinary tract infection 6.4% (placebo 5.5%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400 μg BID
nasopharyngitis 6.3% (placebo 3.7%)
NCT01471171 · Phase 3 · registry result, not featured evidence
400 µg BID
nasopharyngitis 6.4% (placebo 2.4%)
headache 3.5% (placebo 4.7%)
NCT01462929 · Phase 3 · registry result, not featured evidence
400µg
chronic obstructive pulmonary disease 19.9%
NCT01044459 · Phase 3 · registry result, not featured evidence
200µg
chronic obstructive pulmonary disease 19.3%
NCT01044459 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 22.6%
nasopharyngitis 9.4%
urinary tract infection 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 30.4%
contusion 10.9%
cough 8.7%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 24.7%
nasopharyngitis 8.6%
back pain 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 36.4%
sinusitis 11.4%
upper respiratory tract infection 11.4%
NCT00970268 · Phase 3 · registry result, not featured evidence
cough 5.8% (placebo 3.2%)
headache 5.8% (placebo 7.4%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT00500318 · Phase 3 · registry result, not featured evidence
400 μg Bid
diarrhoea 6.9% (placebo 0%)
chronic obstructive pulmonary disease 0% (placebo 10%)
NCT00868231 · Phase 2 · registry result, not featured evidence
100/62.5/25e
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for 31 of these studies.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide

FEV1 Trough 1.422 vs 1.356 placebo L @ 28wk200 μg Once-daily
absolute value · L
NCT00363896 · Phase 3 · monotherapy
show 1 more result
1.428 vs 1.366 placebo L @ 12wk200 μg Once-daily
NCT00363896 · Phase 3 · monotherapy
Time to First Exacerbation NA vs NA placebo months @ 52wk200 μg Once-daily
time to event · months
NCT00363896 · Phase 3 · monotherapy
SGRQ 57.3% (n=269) vs 41% (n=271) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
show 3 more results
48.1% (n=591) vs 39.5% (n=200) placebo @ 52wk200 μg Once-daily
Yes (% Patients with 4-unit decrease)
NCT00363896 · Phase 3 · monotherapy
39% (n=574) vs 32.8% (n=195) placebo @ 52wk200 μg once-daily
Yes (% Patients with 4-unit decrease)
NCT00358436 · Phase 3 · monotherapy
56% (n=275) vs 41% (n=271) placebo @ 24wk200 μg Bid
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
FEV1 Change 1h 0.248 vs -0.05 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 8 more results
0.156 vs -0.05 placebo L @ 24wk400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.253 vs 0.169 AB L @ 24wk400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
0.198 vs -0.086 placebo L @ 52wk400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
0.166 vs -0.086 placebo L @ 52wk400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
0.247 vs -0.037 placebo L @ 24wk400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.269 vs -0.03 placebo L @ 24wk400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0.213 vs -0.03 placebo L @ 24wk400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
FEV1 Peak 0.324 vs 0.008 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 8 more results
0.225 vs 0.008 placebo L @ 24wk400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.263 vs 0.071 placebo L @ 12wk400µg
NCT00891462 · Phase 3
0.212 vs 0.087 placebo L @ 12wk400 μg
NCT01045161 · Phase 3
0.231 vs 0.022 placebo L @ 24wk400 μg Bid
NCT01001494 · Phase 3
0.1605 vs -0.0149 placebo L @ 3wk400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
0.217 vs 0.071 placebo L @ 12wk200 µg
NCT00891462 · Phase 3
0.202 vs 0.087 placebo L @ 12wk200 μg
NCT01045161 · Phase 3
0.206 vs 0.022 placebo L @ 24wk200 μg Bid
NCT01001494 · Phase 3
FEV1 AUC0-12h 0.183 vs -0.026 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 4 more results
0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.23 vs 0.016 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.151 vs -0.026 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.128 vs -0.026 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC 12-24h 0.086 vs -0.103 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.032 vs -0.128 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.174 vs -0.032 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.202 vs -0.06 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.047 vs -0.103 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.044 vs -0.103 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC(0-24h 0.133 vs -0.062 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.065 vs -0.085 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.226 vs -0.006 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.211 vs -0.024 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.1 vs -0.062 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.088 vs -0.062 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 Trough 0.048 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.072 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.029 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.034 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
FEV1 Peak 0.172 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.214 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.176 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.185 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
TDI Focal 56.9% (n=262) vs 45.5% (n=257) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
show 1 more result
53.3% (n=270) vs 45.5% (n=257) placebo @ 24wk200 μg Bid
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
Exacerbation Hospitalization Rate Annualized 0.07 vs 0.1 placebo count @ 52wk
event rate · count
NCT01966107 · Phase 4

+ 25 further endpoints in the CSV export.

fluticasone furoate/umeclidinium/vilanterol

Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
FEV1 0.132 L @ 12wk
absolute change · L
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 86% (n=422) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 47.5% (n=1539) vs 39.9% (n=1543) Non-Ellipta @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
responder rate · % of participants
NCT03467425 · Phase 4 · registry result, not featured evidence · converted to % from 731 Participants as posted
FEV1 1.446 vs 1.396 Non-Ellipta L @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
absolute change · L
NCT03467425 · Phase 4 · registry result, not featured evidence
FEV1 Wm0 24 h 0.039 vs 0.029 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
absolute change · L
NCT03478696 · Phase 4 · registry result, not featured evidence
show 5 more results
0.045 vs 0.041 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.04 vs 0.023 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.045 vs 0.03 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.054 vs 0.063 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.046 vs 0.032 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape